A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants With Spinal Muscular Atrophy With Open-Label Extension
Latest Information Update: 30 Nov 2024
At a glance
- Drugs Taldefgrobep alfa (Primary)
- Indications Spinal muscular atrophy
- Focus Registrational; Therapeutic Use
- Acronyms RESILIENT
- Sponsors Biohaven Pharmaceuticals
Most Recent Events
- 25 Nov 2024 According to a Biohaven Labs media release, evaluation of additional RESILIENT clinical and biomarker data is ongoing, and the company plans to engage with FDA regarding these emerging data to discuss a path forward.Full topline data will be presented at an upcoming scientific meeting.
- 25 Nov 2024 Results presented in a Biohaven Labs Media Release.
- 12 Nov 2024 According to a Biohaven Pharmaceuticals media release, the company plans to report topline data from Phase 3 trial with taldefgrobep in SMA in 4Q 2024.